These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Placing bets on biotech. Weintraub K Cancer Discov; 2011 Nov; 1(6):462. PubMed ID: 22586641 [No Abstract] [Full Text] [Related]
3. Business barriers slowing the pace of cancer immunotherapy research and development. Tuma RS J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521 [No Abstract] [Full Text] [Related]
4. Accelerating identification and regulatory approval of investigational cancer drugs. Esserman LJ; Woodcock J JAMA; 2011 Dec; 306(23):2608-9. PubMed ID: 22187281 [No Abstract] [Full Text] [Related]
5. America's other drug problem: how the drug industry distorts medicine and politics. Relman AS; Angell M New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803 [No Abstract] [Full Text] [Related]
6. Expensive cancer therapies: unintended effects. Delude CM J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602 [No Abstract] [Full Text] [Related]
7. GlaxoSmithKline cancer drug threatens Herceptin market. Waltz E Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273 [No Abstract] [Full Text] [Related]
8. Scripps boosts research coffers by selling reagents to Sigma-Aldrich. Ratner M Nat Biotechnol; 2013 Oct; 31(10):862-4. PubMed ID: 24104735 [No Abstract] [Full Text] [Related]
9. India's drug tests. Padma TV Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471 [No Abstract] [Full Text] [Related]
10. Will the RACE for Children Act lead to new treatments for pediatric cancer? Fink JL Cancer; 2017 Jan; 123(2):189. PubMed ID: 28067946 [No Abstract] [Full Text] [Related]
12. Getting it right: industry sponsorship and medical research. Baird P CMAJ; 2003 May; 168(10):1267-9. PubMed ID: 12743071 [No Abstract] [Full Text] [Related]
13. Biotech firm faces challenges from FDA, falling stock prices. Reynolds T J Natl Cancer Inst; 2002 Mar; 94(5):326-8. PubMed ID: 11880468 [No Abstract] [Full Text] [Related]
14. US presidential candidates diverge on how to help biopharma. Matthews S Nat Med; 2012 Oct; 18(10):1445. PubMed ID: 23042331 [No Abstract] [Full Text] [Related]
15. The NIH, research institutions and industry: working together on a shared goal. Omary MB Gastroenterology; 2007 May; 132(5):1647-50. PubMed ID: 17484859 [No Abstract] [Full Text] [Related]
16. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008. Shumoogam J; Al-Shamahi A IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677 [TBL] [Abstract][Full Text] [Related]
17. The seamless approach to drug development in oncology. Pazdur R Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356 [No Abstract] [Full Text] [Related]
18. What's wrong with money in science. Stossel T; Shaywitz D Washington Post; 2006 Jul; ():B3. PubMed ID: 16838447 [No Abstract] [Full Text] [Related]
19. Charities seek cut of drug royalties. Ledford H Nature; 2011 Jul; 475(7356):275-6. PubMed ID: 21776052 [No Abstract] [Full Text] [Related]